Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
World Neurosurg ; 167: e236-e250, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35944860

ABSTRACT

BACKGROUND: Skull base lesions within the middle cranial fossa (MCF) remain challenging. Recent reports suggest that transorbital endoscopic approaches (TOEAs) might be particularly suitable to access the MCF and expose the lateral wall of the cavernous sinus and the Meckel's cave. METHODS: The present study was developed to compare the nuances of the subtemporal approach (STA) with those of the lateral TOEA (LTOEA) to the MCF and posterior cranial fossa (PCF) in cadaveric specimens. After orbital craniectomy, interdural opening of the cavernous sinus lateral wall (CSlw), exposure of the Gasserian ganglion, and extradural elevation of the temporal lobe was performed. Next, anterior endoscopic petrosectomy was performed and the PCF was accessed. We quantitatively analyzed and compared the angles of attack and distances between LTOEA and STA to different structures at the CSlw, petrous apex (PA), and PCF. RESULTS: Cadaveric dissection through the LTOEA completely exposed the CSlw and PA. LTOA exhibited larger distances than the STA to all targets. Importantly, these differences were greater at the PA and its surrounding key anatomic landmarks. The horizontal and vertical angles of attack allowed by the LTOA were smaller both for the CSlw and PA. However, these differences were not significant for the vertical angle of attack at the CSlw. CONCLUSIONS: LTOEA provides a direct ventral route to the medial aspect of MCF, PA, and PCF. Although TOEAs are versatile approaches, the unfamiliar surgical anatomy and limited instrument maneuverability demand extensive cadaveric dissection before moving to the clinical setting.


Subject(s)
Cranial Fossa, Posterior , Skull Base , Humans , Skull Base/surgery , Skull Base/anatomy & histology , Cranial Fossa, Posterior/surgery , Cranial Fossa, Posterior/anatomy & histology , Endoscopy/methods , Cranial Fossa, Middle/surgery , Cranial Fossa, Middle/anatomy & histology , Cadaver
2.
Cureus ; 13(8): e17012, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34405079

ABSTRACT

Introduction The aim of this study is to determine the efficacy and safety of CyberKnife® (Accuray, Inc., Sunnyvale, CA) hypofractionated radiosurgery (HfRS) in the treatment of chordomas and chondrosarcomas. Methods A total of 24 patients retrospectively identified with chordomas (19 patients) or chondrosarcomas (five patients) were treated between 2012 and 2019 with HfRS as monotherapy or an adjuvant, rescue, or combination therapy. Tumors were located in the skull base (75%) and vertebral spine (25%). Of these, 19 patients underwent previous partial resection and four patients received previous conventional external beam radiation therapy (EBRT) (60-74 Gy). Exclusive or rescue HfRS (20 patients) was administered in five fractions with a median dose of 37.5 Gy (30-40 Gy). Combined tomotherapy-EBRT treatment (median dose: 54 Gy) and HfRS (16.5-30 Gy in 3-12 fractions) were performed in four patients with bulky chordomas. Results The median follow-up from HfRS was 28 months. During clinical follow-up, no deaths were registered with overall survival (OS) of 100% and the actuarial local recurrence-free survival (LRFS) was 93% at one year, 85% at three years, and 68% at five years. Acute toxicity related to HfRS was present in a single patient. Conclusions It is seen that HfRS is effective and safe for chordomas and chondrosarcomas, with rates of LRFS comparable to other radiation modalities.

3.
Hum Pathol ; 110: 20-30, 2021 04.
Article in English | MEDLINE | ID: mdl-33321163

ABSTRACT

The immunohistochemistry (IHC) characterization of pituitary transcription factors (PTFs) PIT1, TPIT, and SF1, which enable the identification of three different adenohypophyseal cell lines, has been incorporated into the latest classification system of the World Health Organization (WHO) for pituitary adenomas. This change overturns the concept of the adenoma as solely a hormone producer and classifies these tumors based on their cell lineage. The aim of the study was to provide a diagnostic algorithm, based on IHC expression of hypophyseal hormones with potential use in diagnostic practice, contributing to an improved classification of pituitary adenomas. Our sample included 146 pituitary adenomas previously classified based on hormonal subtypes by IHC (former 2004 WHO criteria) and re-evaluated after the IHC quantification of PIT1, TPIT, and SF1 expression, under WHO 2017 recommendations. We assessed the correlation between expression of PTFs and the classification as per hormonal IHC and correlated clinicopathological profiles based on PTFs. The IHC study of PTFs allowed reclassification of 82% of tumors that were negative for all pituitary hormones, with 21 positive cases for SF1 (reclassified as gonadotroph tumors), 1 positive case for TPIT (reclassified as a corticotroph tumor), and 4 positive cases for PIT1. Using SF1 enabled detection of a substantial portion of gonadotroph tumors, reducing the estimated prevalence of null cell tumors to less than 5%, and identification of plurihormonal pituitary neuroendocrine tumors with PIT1-SF1 coexpression and hormone-negative PIT1s, a group in which we did not observe differences in the clinical behavior compared with the rest of the tumors of the same cell lineage.Our results suggest that applying a diagnostic algorithm based on the study of PTFs could contribute to improving the classification of pituitary adenomas. By adding TPIT assessment, we propose a two-step algorithm, with hypophyseal hormones being used in a selective modality, depending on initial results.


Subject(s)
Neuroendocrine Tumors/pathology , Pituitary Neoplasms/classification , Pituitary Neoplasms/pathology , Transcription Factors/metabolism , Adenoma/metabolism , Adenoma/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Cell Lineage/physiology , Female , Humans , Immunohistochemistry/methods , Male , Middle Aged , Neuroendocrine Tumors/classification , Young Adult
4.
World Neurosurg ; 121: 4-11, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30261373

ABSTRACT

BACKGROUND: Langerhans cell histiocytosis (LCH) is a multisystemic dendritic cell proliferation that is relatively uncommon in adults. Central nervous system LCH outside the pituitary gland is even more uncommon. CASE DESCRIPTION: We report the case of a 42-year-old man who had complained of right-side hemicranial pain and left arm minor paresis. The symptoms were due to a right insular lobe heterogeneous-enhancing lesion associated with extensive vasogenic edema. The first diagnostic impression suggested glioblastoma multiforme or localized metastasis. The thoracic, abdominal, pelvic computed tomography scan only detected small upper lung inactive nodules suggesting silent focal LCH. A very hard lesion was almost completely removed through a pterional craniotomy approach, with no fluorescence after aminolevulinic acid infusion. The intraoperative biopsy findings ruled out glioma but could not confirm lymphoma. The definitive cerebral biopsy findings showed lymphocytes and histiocytes (CD1a+, S-1001+), with a diagnosis of intracerebral parenchymal LCH. Fractioned radiotherapy resulted in clinical and radiological remission. CONCLUSIONS: The present case is so rare it should not be used as a guide. We probably will never see a single intraparenchymal supratentorial central nervous system LCH lesion. However, we hope our report will help colleagues in the future with the thought process.


Subject(s)
Antigens, CD1/metabolism , Brain Neoplasms/secondary , Cerebral Cortex/pathology , Glioblastoma/secondary , Histiocytosis, Langerhans-Cell/pathology , Lung Neoplasms/physiopathology , Adult , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/physiopathology , Cerebral Cortex/diagnostic imaging , Glioblastoma/diagnostic imaging , Glioblastoma/surgery , Histiocytosis, Langerhans-Cell/complications , Histiocytosis, Langerhans-Cell/diagnostic imaging , Histiocytosis, Langerhans-Cell/surgery , Humans , Lung/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/surgery , Magnetic Resonance Imaging , Male , Tomography Scanners, X-Ray Computed
5.
Rev. mex. ortop. traumatol ; 5(3): 78-81, mayo-jun. 1991. ilus, tab
Article in Spanish | LILACS | ID: lil-102311

ABSTRACT

Se presenta el diseño de un nuevo clavo centromedular, cuyas características le conceden la propiedad de dar compresión axial y estabilidad a un hueso tubular, que permite la consolidación primaria y la rehabilitación temprana del paciente. La compresión axial se logra por medio de una cuerda prominente con machuelo que tiene el clavo en su parte central y que se ajusta distalmente en el conducto medular del fémur y en sentido proximal por medio de una pestaña prominente que topa en el trocánter mayor. El clavo es de una sola pieza. La técnica quirúrgica es fácil, rápida y el instrumental de aplicación es sencillo y de bajo costo. Se presentan los resultados de los primeros ocho pacientes, de 14 a 18 años tratados en el Departamento de Ortopedia del Instituto Nacional de Pediatría de los cuales, a siete se les hizo diafisectomía femoral por desigualdad de los miembros pélvicos y a uno se le dió compresión axial para tratamiento de pseudoartrosis del fémur. En todos los pacientes se utilizó el clavo centromedular de compresión axial. Se comprobó la estabilidad, la compresión axial y la recuperación temprana de los pacientes. El seguimiento a dos años demostró consolidación ósea en el 100%de los casos.


Subject(s)
Humans , Adolescent , Male , Female , Bone Nails , Femoral Fractures/complications , Femoral Fractures/rehabilitation , Femoral Fractures/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...